Phase I study of the combination of monthly carboplatin and weekly cisplatin. 1991

C Sessa, and A Goldhirsch, and G Martinelli, and M Alerci, and L Imburgia, and F Cavalli
Division of Oncology, Ospedale San Giovanni, Bellinzona, Switzerland.

Two cycles of the combination of carboplatin (C), given every 4 weeks with weekly doses of cisplatin (P), were administered on an outpatient basis to 28 previously untreated patients. One cycle consisted of one dose of C and 4 doses of P. The toxicity of 250 mg/m2 of C, combined with escalating doses of P (20, 30, 35, 40 mg/m2) was evaluated first. Thrombocytopenia was dose-limiting and cumulative. At the dose level of 40 mg/m2 of P, the median Pt nadirs during the first and second cycles were 190 (range: 44 to 232) x 10(3)/microL and 90 (range: 15 to 165) x 10(3)/microL, respectively. The median delivered dose intensity (DI) of P was 40 mg/m2/wk in the first cycle and 40 mg/m2/wk in the second cycle. In the second part of the study, 40 mg/m2 of P were combined with a C dose adapted to individual renal function according to the formula dose (mg) = AUC x (GFR + 25) where AUC = 4.5 mg/mL/min. The administration of doses of C ranging from 219 to 493 mg/m2 was associated with a more severe and more variable thrombocytopenia, more frequent P delays and decrease of the median delivered DI of P (first cycle: 33 mg/m2/wk; second cycle: 32 mg/m2/wk). At all dose levels, leukopenia was mild to moderate, and neurotoxicity and severe GI toxicity were absent. No significant reductions of the creatinine clearance values were observed. All patients treated at 40 mg/m2 of P suffered from cumulative subjective toxicity during the second month of therapy.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009325 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females

Related Publications

C Sessa, and A Goldhirsch, and G Martinelli, and M Alerci, and L Imburgia, and F Cavalli
September 1996, Lung cancer (Amsterdam, Netherlands),
C Sessa, and A Goldhirsch, and G Martinelli, and M Alerci, and L Imburgia, and F Cavalli
August 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
C Sessa, and A Goldhirsch, and G Martinelli, and M Alerci, and L Imburgia, and F Cavalli
October 1997, American journal of clinical oncology,
C Sessa, and A Goldhirsch, and G Martinelli, and M Alerci, and L Imburgia, and F Cavalli
June 1996, American journal of clinical oncology,
C Sessa, and A Goldhirsch, and G Martinelli, and M Alerci, and L Imburgia, and F Cavalli
January 1991, Der Urologe. Ausg. A,
C Sessa, and A Goldhirsch, and G Martinelli, and M Alerci, and L Imburgia, and F Cavalli
December 1987, American journal of clinical oncology,
C Sessa, and A Goldhirsch, and G Martinelli, and M Alerci, and L Imburgia, and F Cavalli
August 1997, Gynecologic oncology,
C Sessa, and A Goldhirsch, and G Martinelli, and M Alerci, and L Imburgia, and F Cavalli
December 1994, Gan to kagaku ryoho. Cancer & chemotherapy,
C Sessa, and A Goldhirsch, and G Martinelli, and M Alerci, and L Imburgia, and F Cavalli
October 1992, Gan to kagaku ryoho. Cancer & chemotherapy,
C Sessa, and A Goldhirsch, and G Martinelli, and M Alerci, and L Imburgia, and F Cavalli
December 2009, Gynecologic oncology,
Copied contents to your clipboard!